Lower vs. standard radiation for early nasopharyngeal cancer
Part of Cancer, Ear, nose & throat clinical trials.
This trial compares a lower dose of radiation to the standard dose for people with early-stage nasopharyngeal cancer. It aims to see if a lower dose is just as effective while reducing side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 70 years old.
- You have a newly diagnosed type of nasopharyngeal cancer called non-keratinizing (WHO type II or III) that is stage I (early, hasn't spread).
- After 50.88 Gy of radiation, your tumor completely disappeared and blood tests show no detectable EBV DNA.
- You are in good general health (ECOG score 0-1) and your blood counts, liver, and kidney function are within acceptable ranges.
- You have not had radiation, chemotherapy, or targeted therapy for cancer before.
- If you are a woman who could become pregnant, you agree to use contraception during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new way to shape the radiation field for nasopharyngeal cancer that has spread into the nasal cavity. The goal is to reduce radiation to the nose while still effectively treating the cancer.
This trial tests a combination of low-dose radiation, chemotherapy, and immunotherapy for nasopharyngeal cancer that has spread to the liver. It aims to see if this approach can help shrink tumors and improve outcomes.
This trial compares a lower dose of radiation to the standard dose for people with advanced nasopharyngeal cancer that shrank after chemotherapy and immunotherapy. The goal is to see if a lower dose works just as well with fewer side effects.
This trial tests whether a smaller radiation treatment area is as effective as the usual larger one for people whose metastatic nasopharyngeal cancer has responded well to first-line chemotherapy plus immunotherapy. It aims to reduce side effects while keeping the cancer under control.
This Phase 3 study tests whether giving a reduced amount of radiotherapy can work as well as the standard dose for certain people with stage II–III nasopharyngeal cancer who respond well after initial chemotherapy. It’s designed for patients whose cancer markers improve after 3 chemotherapy cycles, to potentially reduce treatment side effects while keeping cancer control.
This trial compares two approaches for people with early-stage nasopharyngeal cancer that can be removed with surgery. It tests whether giving less intense chemotherapy and radiation after surgery works as well as a standard dose, with fewer side effects.
Hear when a new Nasopharyngeal Cancinoma (NPC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.